Xiqing plus probiotics to improve gut balance and drug effects in chronic kidney disease
Official title: The Effect and Mechanism of Xiqing Regulating Intestinal Homeostasis on Drug Efficacy of Chronic Kidney Disease
Run by Tongji Hospital · NCT07182942 · Data updated 2026-11-12
This trial will test whether adding Xiqing and probiotics helps lower nitrogen waste and improve drug effectiveness in adults with stage 3–5 chronic kidney disease who are not on dialysis.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Tongji Hospital Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Status | Recruiting |
| Started | June 7, 2024 |
| Main results expected | November 30, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | September 19, 2025 |
| Trial ID | NCT07182942 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–75 with non-dialysis CKD stage 3–5 who are clinically stable, able to tolerate Xiqing and probiotics, and can provide informed consent are ideal candidates.
✕Probably not a fit
Patients who are on dialysis, have unstable vital signs or active severe infections, are pregnant or lactating, or who cannot tolerate Xiqing or probiotics are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with CKD stage 3–5 who are not on dialysis will receive Xiqing (an adsorbent intended to remove nitrogenous waste) together with probiotic supplementation to try to modify intestinal homeostasis and influence drug effectiveness. The phase 4 interventional study is conducted at Tongji Hospital in Wuhan and follows patients through a treatment period with planned biochemical and clinical monitoring. Key outcomes will focus on nitrogen waste levels, kidney function markers (such as eGFR, creatinine, and urea), and changes in gut microbiota or metabolite profiles. Safety and tolerability of the combined regimen, including any adverse reactions to Xiqing or probiotics, will be tracked throughout the study.
Why it matters
Potential benefit: If successful, the combination could reduce the burden of nitrogenous wastes, improve how well medications work, and potentially delay progression toward dialysis for some CKD patients.
How similar studies have gone: There is growing evidence that gut-targeted approaches (including probiotics) can affect nitrogen metabolism and CKD outcomes, but combining an adsorbent like Xiqing with probiotics in this context is relatively novel with limited prior direct trial data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Written informed consent was obtained; 2. ranging in age from 18 to 75 years; 3. CKD stage 3-5, that is, eGFR \< 60 mL/min/1.73 m2 with non-dialysis stage, no dialysis indication, temporarily stable condition and drug control stage; 4. tolerance of Xiqing and probiotics treatment. Exclusion Criteria: 1. with severe active infection, influence of nutritional status in patients with malignant tumor and other diseases; 2. patients during pregnancy or lactation; 3. unstable vital signs, the condition is not stable, need dialysis patients; 4. patients with intolerance of Xiqing; 5. patients with intolerance of probiotics; 6. taking corticosteroids, antibiotics or other immunosuppressive agents within the past 3 months; 7. taking adsorbent drugs, such as medicinal charcoal tablets, within the past 3 months.
Where it's running
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China Recruiting
Study contacts
- Study coordinator: Chujin Cao, PhD
- Email: ccj9501@163.com
- Phone: +86 18202742892
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Fostering Self-Empowerment in CKD Patients Through Food Choice Mapping
This project tests a Renal dining map app to help CKD patients in Singapore choose foods when dining out and see if it improves empowerment and well‑being.
-
Self-Management Data and Disease Progression in CKD
This study tests whether patient-recorded self-management data collected via a mobile app can be linked to CKD progression in adults seen at a university hospital.
-
Enarodustat for Anemia in Non-Dialysis CKD Patients
This study tests whether enarodustat can help increase hemoglobin safely in adults with CKD who aren’t on dialysis, grouping participants by inflammation level.
-
Periodontal Health in Rare Kidney Conditions and Controls
This study tests how common periodontitis is in people with rare kidney disorders and compares it to CKD patients and people without kidney disease.
-
AdiaVita regenerative therapy for chronic kidney disease
This trial tests whether AdiaVita (umbilical cord blood stem cells and exosomes plus glutathione) can improve kidney function in adults with stage 2–4 chronic kidney disease.
-
HTD1801 vs placebo for kidney protection in type 2 diabetes and CKD
This trial tests whether HTD1801 can slow kidney decline in adults with type 2 diabetes and chronic kidney disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.